Citations

Clear

3942 citation(s) found for "To, Van".

Risk of De Novo Hepatocellular Carcinoma Following Use of Direct Acting Antiviral Medications for Treatment of Chronic Hepatitis C
Antwi, Samuel O. , Houten, Holly K. Van , Sangaralingham, Lindsey R. , Van Houten, Holly K, Antwi, Samuel O , Patel, Tushar

Mayo Clinic

Cancer Prevention Research | August 26, 2019 | Volume: 12 | Issue: 12 | Pages: 891-902

10.1158/1940-6207.capr-19-0162 | PMID 31451519 Get It

Abstract Direct-acting antivirals (DAA) are now the mainstay of treatment for patients with chronic hepatitis C virus (HCV); however, there is some controversy over whether use of DAAs for HCV, as compared with IFN-based regimens, leads to an increased risk for hepatocellular carcinoma (HCC) development. We investigated the association between use of DAAs and subsequent development of HCC in longitudinal data from patients with HCV from diverse backgrounds (various ages, ethnicities, and geographic regions) across the United States. The design was a retrospective study performed using medical and pharmacy claims from OptumLabs. HCV treatment exposure was categorized as DAA-only, DAA + IFN, any-DAA, or IFN-only. To account for confounding by indication, inverse probability of treatment weighting was performed. Cox proportional hazard models were used to calculate hazard ratios (HR) and 95% confidence intervals (CI). We identified 5,781 patients with HCV with no history of HCC at baseline. Compared with IFN-only regimen, no significant increase in HCC risk was found for use of DAA-only (HR, 1.53; 95% CI, 0.73–3.23), DAA + IFN (HR, 1.02; 95% CI, 0.51–2.06), or any-DAA (HR, 1.04; 95% CI, 0.65–1.65). When stratified by sustained virological response (SVR), we noted a higher HCC risk for DAA-only among patients who achieved SVR post-treatment (HR, 7.53; 95% CI, 1.48–38.34), but the CIs were wide, which might be due to the small sample size of the subgroups. Among those who did not achieve SVR, no association was found for use of DAA-only (HR, 0.59; 95% CI, 0.19–1.91). These findings do not provide compelling evidence for the conception that use of DAAs for HCV is associated with increased risk of HCC development.
Galectin-3 Plasma Levels and Secretion Mechanism in Idiopathic Pulmonary Fibrosis
Shaughnessy, Gaja F., Egan, Ashley M. , Dasari, Harika , Kuelen, V. Van, Peikert, Tobias, Porquera, Eva M. Carmona, Ali, M.

Mayo Clinic

C58. MECHANISMS OF PULMONARY FIBROSIS | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5233-A5233

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5233 Get It

Microglia in frontotemporal lobar degeneration with progranulin or C9ORF72 mutations
Sakae, Nobutaka, Roemer, Shanu F. , Bieniek, Kevin F. , Murray, Melissa E. , Kasanuki, Koji , Graff‐Radford, Neill R. , Petrucelli, Leonard , Blitterswijk, Marka van , Rademakers, Rosa , Baker, Matthew C, Dickson, Dennis W , van Blitterswijk, Marka , Murray, Melissa E , Baker, Matthew , Dickson, Dennis W.

Mayo Clinic

Annals of Clinical and Translational Neurology | August 26, 2019 | Volume: 6 | Issue: 9 | Pages: 1782-1796

10.1002/acn3.50875 | PMID 31448566 Get It

AbstractObjectiveTo identify clinicopathological differences between frontotemporal lobar degeneration (FTLD) due to mutations in progranulin (FTLD‐GRN) and chromosome 9 open reading frame 72 (FTLD‐C9ORF72).MethodsWe performed quantitative neuropathologic comparison of 17 FTLD‐C9ORF72 and 15 FTLD‐GRN with a focus on microglia. For clinical comparisons, only cases with high quality medical documentation and concurring diagnoses by at least two neurologists were included (14 FTLD‐GRN and 13 FTLD‐C9ORF72). Neuropathological analyses were limited to TDP‐43 Type A to assure consistent assessment between the groups, acknowledging that Type A is a minority of C9ORF72 patients. Furthermore, only cases with sufficient tissue from all regions were studied (11 FTLD‐GRN and 11 FTLD‐C9ORF72). FTLD cases were also compared to age– and sex–matched normal controls. Immunohistochemistry was performed for pTDP‐43, IBA‐1, CD68, and GFAP. Morphological characterization of microglia was performed in sections of cortex blinded to clinical and genetic information.ResultsFTLD‐GRN patients had frequent asymmetric clinical features, including aphasia and apraxia, as well as more asymmetric cortical atrophy. Neuropathologically, FTLD‐C9ORF72 had greater hippocampal tau pathology and more TDP‐43 neuronal cytoplasmic inclusions. FTLD‐GRN had more neocortical microvacuolation, as well as more IBA‐1–positive ameboid microglia in superficial cortical layers and in subcortical white matter. FTLD‐GRN also had more microglia with nuclear condensation, possibly indicating apoptosis. Microglial morphology with CD68 immunohistochemistry in FTLD‐GRN and FTLD‐C9ORF72 differed from controls.InterpretationOur findings underscore differences in microglial response in FTLD‐C9ORF72 and FTLD‐GRN as shown by significant differences in ameboid microglia in gray and white matter. These results suggest the differential contribution of microglial dysfunction in FTLD‐GRN and FTLD‐C9ORF72 and suggest that clinical, neuroimaging and pathologic differences could in part be related to differences in microglia response.
Concordance of Patient and Caregiver Reports on the Quality of Colorectal Cancer Care
Havyer, Rachel D. , Ryn, Michelle van , Wilson, Patrick M. , Bangerter, Lauren R. , Griffin, Joan M. , van Ryn, Michelle

Mayo Clinic

Journal of Oncology Practice | August 20, 2019 | Volume: 15 | Issue: 11 | Pages: e979-e988

10.1200/jop.19.00136 | PMID 31430216 Get It

PURPOSE: We aimed to better understand how similarly patients with colorectal cancer and caregivers view care quality and to assess factors that may influence concordance. MATERIALS AND METHODS: We conducted a secondary analysis of paired patient and caregiver quality ratings of colorectal cancer care in three specific domains: surgery, chemotherapy overall, and chemotherapy nursing. Agreement was assessed with difference scores, concordance with Gwet second-order agreement statistics (AC2), and variation in agreement with stratified analyses. We examined whether the care experiences of patients and caregivers were associated with top-box (most-positive) ratings and examined variations in concordance on the basis of the presence of a top-box score. RESULTS: Four hundred seventeen patient-caregiver dyads completed the surveys. Quality-of-care ratings were positively skewed, with most dyads indicating top-box ratings. Patient and caregiver care experiences were highly associated with top-box ratings. Overall patient-caregiver concordance was very high for all three care domains (surgery: AC2, 0.87 [95% CI, 0.83 to 0.90]; chemotherapy overall: AC2, 0.84 [95% CI, 0.79 to 0.88]; chemotherapy nursing: AC2, 0.91 [95% CI, 0.87 to 0.94]). Stratified analyses of patient and caregiver characteristics did not identify any patterns that consistently affected concordance. The concordance statistic significantly decreased for all three outcomes ( P < .001), however, when the patient or caregiver assessed quality as anything other than top box. CONCLUSION: Caregiver and patient reports on care quality were highly concordant for top-box care and did not vary with patient or caregiver factors. Additional exploration is needed to identify reasons for increased variability when the quality scores were less than a top-box response.
Development of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of progression
Overbeek, Kasper A. , Alblas, Maaike , Gausman, Valerie , Kandel, Pujan , Schweber, Adam B. , Brooks, Christian , Riet, Priscilla A. van , Wallace, Michael B. , Gonda, Tamas A. , Cahen, Djuna L. , Bruno, Marco J. , Van Riet, Priscilla A , Wallace, Michael B

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 20, 2019 | Volume: 50 | Issue: 7 | Pages: 789-799

10.1111/apt.15440 | PMID 31429105 Get It

SummaryBackgroundBecause most pancreatic intraductal papillary mucinous neoplasms (IPMNs) will never become malignant, currently advocated long‐term surveillance is low‐yield for most individuals.AimTo develop a score chart identifying IPMNs at lowest risk of developing worrisome features or high‐risk stigmata.MethodsWe combined prospectively maintained pancreatic cyst surveillance databases of three academic institutions. Patients were included if they had a presumed side‐branch IPMN, without worrisome features or high‐risk stigmata at baseline (as defined by the 2012 international Fukuoka guidelines), and were followed ≥ 12 months. The endpoint was development of one or more worrisome features or high‐risk stigmata during follow‐up. We created a multivariable prediction model using Cox‐proportional logistic regression analysis and performed an internal‐external validation.Results875 patients were included. After a mean follow‐up of 50 months (range 12‐157), 116 (13%) patients developed worrisome features or high‐risk stigmata. The final model included cyst size (HR 1.12, 95% CI 1.09‐1.15), cyst multifocality (HR 1.49, 95% CI 1.01‐2.18), ever having smoked (HR 1.40, 95% CI 0.95‐2.04), history of acute pancreatitis (HR 2.07, 95% CI 1.21‐3.55), and history of extrapancreatic malignancy (HR 1.34, 95% CI 0.91‐1.97). After validation, the model had good discriminative ability (C‐statistic 0.72 in the Mayo cohort, 0.71 in the Columbia cohort, 0.64 in the Erasmus cohort).ConclusionIn presumed side branch IPMNs without worrisome features or high‐risk stigmata at baseline, the Dutch‐American Risk stratification Tool (DART‐1) successfully identifies pancreatic lesions at low risk of developing worrisome features or high‐risk stigmata.
Transcriptomic Analysis of Cellular Pathways in Healing Flexor Tendons of Plasminogen Activator Inhibitor 1 (PAI‐1/Serpine1) Null Mice
Freeberg, M.A.T. , Easa, Anas, Lillis, Jacquelyn, Benoit, Danielle S. W. , Wijnen, André J. van , Awad, Hani A. , van Wijnen, Andre J , Awad, Hani A

Mayo Clinic

Journal of Orthopaedic Research | August 19, 2019 | Volume: 38 | Issue: 1 | Pages: 43-58

10.1002/jor.24448 | PMID 31424116 Get It

ABSTRACTInjuries to flexor tendons can be complicated by fibrotic adhesions, which severely impair the function of the hand. Plasminogen activator inhibitor 1 (PAI‐1/SERPINE1), a master suppressor of fibrinolysis and protease activity, is associated with adhesions. Here, we used next‐generation RNA sequencing (RNA‐Seq) to assess genome‐wide differences in messenger RNA expression due to PAI‐1 deficiency after zone II flexor tendon injury. We used the ingenuity pathway analysis to characterize molecular pathways and biological drivers associated with differentially expressed genes (DEG). Analysis of hundreds of overlapping and DEG in PAI‐1 knockout (KO) and wild‐type mice (C57Bl/6J) during tendon healing revealed common and distinct biological processes. Pathway analysis identified cell proliferation, survival, and senescence, as well as chronic inflammation as potential drivers of fibrotic healing and adhesions in injured tendons. Importantly, we identified the activation of PTEN signaling and the inhibition of FOXO1‐associated biological processes as unique transcriptional signatures of the healing tendon in the PAI‐1/Serpine1 KO mice. Further, transcriptomic differences due to the genetic deletion of PAI‐1 were mechanistically linked to PI3K/Akt/mTOR, PKC, and MAPK signaling cascades. These transcriptional observations provide novel insights into the biological roles of PAI‐1 in tendon healing and could identify therapeutic targets to achieve scar‐free regenerative healing of tendons. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:43–58, 2020
Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism
Lindström, Sara , Wang, Lu , Smith, Erin N. , Gordon, William, Vlieg, Astrid van Hylckama , Andrade, Mariza de , Brody, Jennifer A. , Pattee, Jack , Haessler, Jeffrey, Brumpton, Ben , Suchon, Pierre , Chen, Ming‐Huei , Germain, Marine , Wiggins, Kerri L. , Brækkan, Sigrid K. , Armasu, Sebastian M. , Jackson, Rebecca D., Giulianini, Franco, Puurunen, Marja , Ibrahim, Manal , Heckbert, Susan R. , Natarajan, Pradeep , Klarin, Derek , Program, The Million Veteran, Vries, Paul S. de , Sabater‐Lleal, Maria , Group, The CHARGE Hemostasis Working, Bammler, Theo K. , Frazer, Kelly A. , McCauley, Bryan M. , Pankow, James S. , Reiner, Alex P. , Gabrielsen, Maiken E. , Kim, Jihye , McKnight, Barbara, Hansen, J.-B., Heit, John A. , Tang, Weihong , Morange, Pierre‐Emmanuel , Johnson, Andrew D. , Kabrhel, Christopher , Trégouët, David‐Alexandre , Smith, Nicholas L. , Assimes, Themistocles L. , Ballantyne, Christie M. , Hansen, John‐Bjarne , Frazer, Kelly A , de Andrade, Mariza , Assimes, Themistocles L , Wiggins, Kerri L , Ballantyne, Christie M , Natarajan, Pradeep , Braekkan, Sigrid K , Germain, Marine , Brumpton, Ben , Sabater-Lleal, Maria , Pankow, James S , Tang, Weihong , Brody, Jennifer A , Chasman, Daniel I. , Turman, Constance , MacDonald, James W. , Pankratz, Nathan , Nielsen, Jonas Bille , Damrauer, Scott M , Program, The Million Veteran, Huffman, Jennifer E. , Group, The CHARGE Hemostasis Working, Taylor, Kent D. , Deleuze, Jean‐François , O'Donnell, Chris J., Kraft, Peter , Rosendaal, Frits R , Psaty, Bruce M. , Kooperberg, Charles , Hveem, Kristian , Ridker, Paul M.

Mayo Clinic

Blood | August 16, 2019 | Volume: 134 | Issue: 19 | Pages: 1645-1657

10.1182/blood.2019000435 | PMID 31420334 Get It

In this work related to familial aggregation of familial venous thromboembolism, the investigators report genomic and transcriptomic association of 16 novel susceptibility loci for venous thromboembolism.
Inhibition of COX‐2 Pathway as a Potential Prophylaxis Against Arthrofibrogenesis in a Rabbit Model of Joint Contracture
Salib, Christopher G. , Reina, Nicolas , Trousdale, William H. , Limberg, Afton K. , Tibbo, Megan E., Jay, Anthony G. , Robin, Joseph X. , Turner, Travis W., Jones, Carter R., Paradise, Christopher R. , Carter, Jodi M. , Berry, Daniel J., Wijnen, André J. van , Berry, Daniel J. , Lewallen, Eric A. , Sanchez-Sotelo, Joaquin, Abdel, Matthew P , van Wijnen, Andre J , van Wijnen, Andre J , Berry, Daniel J , Bolon, Brad , Berry, Daniel J., Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Abdel, Matthew P. , Carter, Jodi

Mayo Clinic

Journal of Orthopaedic Research | August 14, 2019 | Volume: 37 | Issue: 12 | Pages: 2609-2620

10.1002/jor.24441 | PMID 31410880 Get It

ABSTRACTArthrofibrosis is a common complication following total knee arthroplasty caused by pathologic fibroblast activation and excessive collagen deposition around a synovial joint leading to debilitating loss of motion. Treatment options are limited because the pathologic mechanisms remain to be characterized. Dysregulation of the inflammatory cascade may lead to communication between myofibroblasts and immune cells triggering tissue metaplasia, and excessive collagen deposition described clinically as arthrofibrosis. We explored the novel use of celecoxib (selective cyclooxygenase‐2 [COX‐2] inhibitor) to disrupt the downstream effects of the post‐traumatic inflammatory cascade and inhibit scar tissue formation in a validated rabbit model of arthrofibrosis combined with new parameters for quantifying the stiffness of the posterior capsule. Biomechanical and molecular analyses, of contracted rabbit knee posterior capsule tissue after COX‐2 inhibition revealed increased maximal passive extension and down‐regulation of collagen messenger RNA compared with controls. Histopathologic examination suggested a trend of decreased quantities of dense fibrous connective tissue with COX‐2 inhibition. These data may suggest that inhibiting the inflammatory cascade could potentially reduce pathologic myofibroblast activation, thereby reducing scar tissue formation and increasing the range of motion in arthrofibrotic joints. Implementing a multi‐modal pharmacologic approach may simultaneously target numerous cellular components contributing to the complex process of arthrofibrogenesis. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:2609–2620, 2019
Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405
Guercio, Brendan J. , Zhang, Sui , Niedzwiecki, Donna , Lenz, Heinz‐Josef , Innocenti, Federico , O’Neil, Bert H. , Polite, Blasé N. , Höchster, Howard S. , Atkins, James N., Goldberg, Richard M. , Sato, Kaori , Ng, Kimmie , Blarigan, Erin Van, Blanke, Charles D. , O’Reilly, Eileen M. , Fuchs, Charles S. , Meyerhardt, Jeffrey A. , Meyerhardt, Jeffrey A , O'Reilly, Eileen M , Niedzwiecki, Donna , Ou, Fang‐Shu , Venook, Alan P. , Shaw, James Edward , Blarigan, Erin L. Van , Mayer, Robert J.

Mayo Clinic

Journal of Clinical Oncology | August 13, 2019 | Volume: 37 | Issue: 29 | Pages: 2620-2631

10.1200/jco.19.01019 | PMID 31408415 Get It

PURPOSERegular physical activity is associated with reduced risk of recurrence and mortality in patients with nonmetastatic colorectal cancer. Its influence on patients with advanced/metastatic colorectal cancer (mCRC) has been largely unexplored.PATIENTS AND METHODSWe conducted a prospective cohort study nested in Cancer and Leukemia Group B (Alliance)/SWOG 80405 (ClinicalTrials.gov identifier: NCT00265850 ), a National Cancer Institute–sponsored phase III trial of systemic therapy for mCRC. Within 1 month after therapy initiation, patients were invited to complete a validated questionnaire that reported average physical activity over the previous 2 months. On the basis of responses, we calculated metabolic equivalent task (MET) hours per week to quantify physical activity. The primary end point of the clinical trial and this companion study was overall survival (OS). Secondary end points included progression-free survival (PFS) and first grade 3 or greater treatment-related adverse events. To minimize confounding by poor and declining health, we excluded patients who experienced progression or died within 60 days of activity assessment and used Cox proportional hazards regression analysis to adjust for known prognostic factors, comorbidities, and weight loss.RESULTSThe final cohort included 1,218 patients. Compared with patients engaged in less than 3 MET hours per week of physical activity, patients engaged in 18 or more MET hours per week experienced an adjusted hazard ratio for OS of 0.85 (95% CI, 0.71 to 1.02; PTrend= .06) and for PFS of 0.83 (95% CI, 0.70 to 0.99; PTrend= .01). Compared with patients engaging in less than 9 MET hours per week, patients engaging in 9 or more MET hours per week experienced an adjusted hazard ratio for grade 3 or greater treatment-related adverse events of 0.73 (95% CI, 0.62 to 0.86; PTrend< .001).CONCLUSIONAmong patients with mCRC in Cancer and Leukemia Group B (Alliance)/SWOG 80405, association of physical activity with OS was not statistically significant. Greater physical activity was associated with longer PFS and lower adjusted risk for first grade 3 or greater treatment-related adverse events.